Chemed Corporation — 2018 Form 10-K
Business context and reporting period. This is Chemed’s annual report for the fiscal year ended December 31, 2018, not a standalone fourth-quarter filing. Chemed operates two segments: VITAS, a hospice and palliative-care provider, and Roto-Rooter, which provides plumbing, drain-cleaning and water-restoration services.
Financial performance and liquidity
The supplied filing text incorporates the consolidated financial statements and management’s discussion from the 2018 Annual Report to Stockholders but does not reproduce their financial results. It does not provide clear values here for revenue, profit, cash flow, margins, or comparative year-over-year performance; those figures should not be inferred from this excerpt.
- Debt and interest rate exposure: Long-term debt at December 31, 2018 was approximately $89.2 million, all at variable interest rates. The filing states that each 100-basis-point rate change would change annual interest expense by $100,000 for every $10 million borrowed.
- Liquidity: The excerpt does not provide cash, current assets, current liabilities, or unused borrowing capacity. Debt agreements contain financial and operating restrictions, and the company identifies debt-service and refinancing risks.
- Revenue concentration: More than 95% of VITAS revenue came from Medicare and Medicaid; approximately 93% was attributed to Medicare in the business description. The company is therefore substantially exposed to government reimbursement rules and rates.
- Capital returns: Chemed repurchased shares during 2018 under its February 2011 program. The filing reports quarterly purchases but does not provide a clearly stated annual total in the supplied text. The Board authorized an additional $150 million under the program in March 2018. Chemed has historically paid quarterly dividends, subject to earnings, financial condition, debt covenants and other factors.
Changes, outlook and management commentary
- The filing excerpt does not provide a clear financial comparison with 2017 or specific forward guidance. The detailed results and management discussion are incorporated by reference and are not included in the supplied text.
- Roto-Rooter results are sensitive to weather and precipitation; VITAS may see seasonal increases in Florida admissions and revenue during winter months.
- Management describes growth opportunities in new and existing markets, while noting that hospice expansion may depend on staffing, referral relationships, certification and state approvals.
- Key operating pressures include labor and supply cost inflation, difficulty recruiting nurses and licensed plumbers, competition, and potential limits on government reimbursement. VITAS reimbursement increases may not keep pace with actual cost inflation.
Risks, contingencies and unusual items
- VITAS settlement and compliance oversight: In 2017, Chemed paid $75 million plus interest and certain relator fees to settle False Claims Act litigation, without admitting wrongdoing. A previously recorded $90 million reserve was reduced by approximately $5.5 million in the fourth quarter of 2017 after estimated relator fees were lower than expected. VITAS remains subject to a five-year Corporate Integrity Agreement effective October 30, 2017, including monitoring and independent audits; breach could result in penalties or exclusion from federal healthcare programs.
- Claims reviews and reimbursement caps: Medicare and other payors audit hospice claims, which can result in denials or recoupments. Medicare also applies annual hospice payment caps; the overall cap was $28,689.04 per admission for the period ended October 31, 2018.
- Litigation: The company describes California wage-and-hour and related class or representative actions involving VITAS and Roto-Rooter, as well as shareholder derivative litigation. It says it cannot reasonably estimate the probability or range of loss for the listed lawsuits. The shareholder derivative case had a magistrate judge’s recommendation to grant the defendants’ motion to dismiss, subject to further court action.
- Environmental exposure: Chemed recorded a $1.7 million liability for environmental cleanup and related costs associated with the former DuBois business. It is contingently liable for up to an additional $14.9 million; management states that payment of this additional amount is not probable and has not recorded a provision.
- Other principal risks: Government reimbursement changes, regulatory enforcement, staffing shortages, cyber incidents, weather and hurricane exposure in south Florida, debt covenants, competition, and potential environmental or liability claims.
Important facts for investors to verify
- Consult the incorporated 2018 Annual Report and MD&A for revenue, earnings, cash flow, margins, segment performance, liquidity and comparable-period figures; these are not clearly provided in the supplied text.
- Review VITAS’ payer mix, Medicare reimbursement exposure, claims-audit reserves and progress under the Corporate Integrity Agreement.
- Check the full financial statements and credit agreement for debt maturities, covenant headroom, borrowing capacity and cash available for repurchases and dividends.
- Monitor the outcomes and potential costs of the disclosed wage-and-hour and shareholder litigation, and any developments in the DuBois environmental contingency.